Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Alunbrig is a prescription kinase inhibitor containing brigatinib. It is approved for adults with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer confirmed by an FDA-approved test. Alunbrig comes as 30 mg, 90 mg, and 180 mg tablets. Treatment uses a lower dose during the first week before increasing to the standard daily dose.
read more about alunbrig ...Brigatinib is a tyrosine kinase inhibitor with activity against ALK and several other kinases. It inhibits ALK autophosphorylation and downstream signaling proteins involved in cancer-cell growth and survival. In ALK-positive tumor models, brigatinib reduced growth of cells carrying susceptible ALK alterations and showed activity against selected ALK resistance mutations.
Alunbrig is approved for adults with metastatic non-small cell lung cancer whose tumors are positive for anaplastic lymphoma kinase. An FDA-approved test is used to identify eligible tumors. The indication covers metastatic disease and does not extend to every form of non-small cell lung cancer.
The recommended regimen starts with 90 mg by mouth once daily for the first seven days. If tolerated, the dose increases to 180 mg once daily. Tablets are taken with or without food and swallowed whole. If treatment is interrupted for 14 days or longer for reasons other than an adverse reaction, the 90 mg starting period is repeated.
Serious risks include interstitial lung disease or pneumonitis, high blood pressure, slow heart rate, visual disturbances, increased creatine phosphokinase, elevated pancreatic enzymes, liver injury, high blood sugar, photosensitivity, and fetal harm. Monitoring includes blood pressure, heart rate, glucose, liver tests, pancreatic enzymes, and muscle enzymes at specified points during treatment.
Alunbrig is a targeted tyrosine kinase inhibitor rather than traditional cytotoxic chemotherapy.
Yes. It is approved for adults with ALK-positive metastatic non-small cell lung cancer confirmed by an FDA-approved test.
Yes. Alunbrig tablets are taken with or without food and swallowed whole.
The labeled regimen uses 90 mg daily for seven days before increasing to 180 mg daily when tolerated.
ALUNBRIG (brigatinib) for Healthcare Professionals. https://www.alunbrig.com/hcp. Date Accessed September 11, 2026.
ALUNBRIG (brigatinib) Dosing Guide. https://www.alunbrig.com/hcp/sites/default/files/resources/dosing-guide.pdf. Date Accessed September 11, 2026.
Brigatinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a617016.html. Date Accessed September 11, 2026.
Brigatinib. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/brigatinib. Date Accessed September 11, 2026.
DailyMed - ALUNBRIG (brigatinib) Tablet, Film Coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db. Date Accessed September 11, 2026.